Partnership with QIMR Berghofer targets oesophageal cancer

Proteomics International partners with QIMR Berghofer Medical Research Institute (QIMR Berghofer) to improve detection of oesophageal adenocarcinoma, the most common oesophageal cancer.

The Partnership will use the Promarker™ platform with QIMR Berghofer biomarkers to develop a simple blood test for a cancer whose incidence is rising rapidly.

The collaboration is part of Proteomics International’s strategy to continually expand its diagnostics portfolio in areas of significant unmet medical need.

Media Release


  • This field is for validation purposes and should be left unchanged.